오가노이드 및 스페로이드 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Organoids And Spheroids Market Size, Share & Trends Analysis Report By Type (Neurospheres, iPSCs Derived Cells, Hepatic Organoids), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,515,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,946,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,809,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

오가노이드 및 스페로이드 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 오가노이드 및 구형체 시장 규모는 예측 기간 동안 CAGR 23.11%를 기록하며 2030년까지 32억 6,000만 달러에 달할 것으로 예상됩니다.

약물 개발에 있어 오가노이드 배양의 채택이 증가하고 전 세계적으로 세포 치료 및 조직 공학에 대한 수요가 증가함에 따라 시장을 주도할 것으로 예상됩니다.

3차원 구형체는 복잡한 조직과 장기를 생성하기 위한 빌딩 블록으로 사용될 수 있기 때문에 조직 공학 및 재생 의학 연구의 중요한 측면으로 간주됩니다. 또한, 3D 세포 배양은 약물 스크리닝 및 인간 질병의 분석 모델로 사용될 수 있으며, 가까운 미래에 시장에 충분한 성장 기회를 제공할 것으로 예상됩니다.

인체 특이적 질환의 기전 평가에 오가노이드 배양을 도입하는 움직임이 활발해지면서 시장 성장이 기대되고 있습니다. 예를 들어, 인간 오가노이드는 소장, 전립선, 뇌, 간 등 다양한 조직 분석에 활용되고 있습니다. 인간 장기와 유사한 3D 세포 배양의 생성은 세포 치료 및 장기 이식을 대체할 수 있는 세포 치료제로서 오가노이드의 활용 가능성에 큰 잠재력을 가지고 있습니다.

오가노이드 및 구면체 시장 보고서 하이라이트

• 구형 부문은 분석 기간 동안 시장을 지배할 것으로 예상됩니다.
• 신약 개발, 질병 모델링, 안전성 시험 분야에서 3D 스페로이드의 채택이 증가하고 있는 것이 이 분야를 주도하는 주요 요인입니다.
• 인공줄기세포(iPSC)에서 유래한 오가노이드의 개발은 세포 발생의 동적 관찰을 위한 길을 열어 인간 발생 메커니즘 연구의 채택을 촉진하여 발생 생물학 응용 부문이 2023년 가장 큰 매출 점유율을 차지했습니다.
• 2023년 시장에서는 생명공학 및 제약 산업이 최종 용도 부문을 주도하고 있습니다. 이는 제약회사들이 전임상 신약개발에서 오가노이드 및 스페로이드의 활용도가 높기 때문입니다.
• 또한, 이들 기업은 오가노이드 및 구형체의 생성 효율을 높이는 첨단 제품 개발에도 적극 나서고 있습니다.
• 북미 시장은 기술적으로 진보된 세포 배양 플랫폼의 채택률이 높고, 세포 및 장기 연구에 적극적으로 참여하는 대학 및 학술 기관이 많아 2023년 가장 높은 수익을 창출할 것으로 예상됩니다.
• 또한, 북미의 높은 오가노이드 및 구형 배양 제품 채택률과 효율적인 헬스케어 인프라가 북미 매출의 가장 큰 요인으로 작용하고 있습니다.
• 아시아태평양에서는 예측 기간 동안 시장이 유리한 성장을 이룰 것으로 예상됩니다.
• STEMCELL Technologies, Australasian Society for Stem Cell Research(ASSCR), The Japanese Society for Regenerative Medicine, Korean Society for Stem Cell Research(KSSCR)와 같은 주요 기업 및 정부 기관의 존재는 아시아에서 오가노이드 및 구형 배양의 보급을 증가시킬 것으로 예상됩니다.
• 주요 기업들은 시장에서의 지위를 높이기 위해 끊임없이 신제품 연구개발에 힘쓰고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 오가노이드 및 스페로이드 시장 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 오가노이드 및 스페로이드 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 유형 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 형 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 규모와 동향 분석, 유형별, 2018-2030년
• 오가노이드
  • 유형별 오가노이드
  • 방법별 오가노이드
  • 소스별 오가노이드
• 스페로이드
  • 유형별 스페로이드
  • 방법별 스페로이드
  • 소스별 스페로이드

제5장 최종 용도 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 최종 용도 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 규모와 최종 용도별 동향 분석, 2018-2030년
• 바이오테크놀러지와 제약 산업
• 학술연구기관
• 병원 및 진단센터

제6장 용도 비즈니스 분석

• 부문 대시보드
• 세계의 오가노이드 및 스페로이드 시장 : 용도 변동 분석
• 세계의 오가노이드 및 스페로이드 시장 규모와 동향 분석, 용도별, 2018-2030년
• 발생생물학
  • 발생생물학 시장 추산·예측(2018-2030년)
• 맞춤형 의료
  • 맞춤형 의료 시장 추산·예측
• 재생의료
  • 재생의료 시장 추산·예측
• 질환 병리학 연구
  • 질환 병리학 연구 시장 추산·예측(2018-2030년)
• 약물 독성 및 약효 시험
  • 약물 독성 및 유효성 검사 시장 추산·예측(2018-2030년)

제7장 국가, 유형, 용도 및 최종 용도별 지역 비즈니스 분석

• 부문 대시보드
• 장 규모와 예측 및 동향 분석(2018-2030년)
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업 시장 현황 분석, 2023년
• 기업 개요/리스트 표
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Lonza
  • 3D Biomatrix
  • 3D Biotek LLC
  • AMS Biotechnology(Europe) Limited
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology(HUB)
  • InSphero
  • Prellis Biologics
  • STEMCELL Technologies Inc.

LSH

영문 목차

영문목차

Organoids And Spheroids Market Growth & Trends:

The global organoids and spheroids market size is expected to reach USD 3.26 billion by 2030, registering a CAGR of 23.11% during the forecast period, according to a new report by Grand View Research, Inc., A rise in the adoption of organoid cultures in drug discovery, and rising demand for cell therapy and tissue engineering across the globe is expected to drive the market.

3D spheroids are considered as an important aspect of tissue engineering and regenerative medicine research as they can be used as building blocks for the generation of complex tissues and organs. In addition, the potential of 3D cell cultures to be used as models for drug screening and analysis of human disorders are expected to provide ample growth opportunities to the market in the near future.

A rise in the adoption of organoid cultures for the assessment of the mechanism of human-specific disorders is expected to enhance the market growth. For instance, human organoids have helped in the analysis of a wide range of tissues including the small intestine, prostate, brain, and liver. The promise of the generation of 3D cell cultures that resemble human organs has brought an enormous potential for the use of organoids as cell therapies, and as prospective substitutes for whole-organ transplantation.

Organoids And Spheroids Market Report Highlights:

• The spheroids segment is anticipated to dominate the market throughout the analysis period
• Higher adoption of 3D spheroids in the fields of drug discovery, disease modeling, and safety testing is a key factor driving the segment
• The developmental biology application segment accounted for the largest revenue share in 2023 as the development of organoids from Induced Pluripotent Stem Cells (iPSCs) have paved way for dynamic observation of cell development and propelled the adoption of mechanistic studies for human development
• Biotechnology and pharmaceutical industries dominated the end-use segment in the market in 2023. This is because of the high utilization rate of organoids and spheroids in pre-clinical drug discovery by pharma entities
• In addition, these players are actively involved in the development of advanced products that enhance the efficiency of organoid and spheroid generation.
• In North America, the market generated the highest revenue in 2023 due to higher adoption of technologically advanced cell culture platforms, and the presence of a large number of universities and academic institutions actively involved in cell and organ-based studies
• In addition, a higher adoption rate of organoid and spheroid culture products and efficient healthcare infrastructure in North America is attributive to the largest revenue generation from the region
• In Asia Pacific, the market is anticipated to witness lucrative growth over the forecast period.
• Presence of key players and government organizations such as STEMCELL Technologies, Australasian Society for Stem Cell Research (ASSCR), The Japanese Society for Regenerative Medicine, The Korean Society for Stem Cell Research (KSSCR), and others are expected to enhance the penetration of organoid and spheroid culture in Asia
• The key players are constantly involved in research and development of new products so that they can enhance their market position

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Application
  • 1.1.3. End-Use
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Organoids & Spheroids Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High adoption of organoids & spheroids in drug discovery
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising demand for tissue engineering & organ transplantation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Challenges associated with 3D cell culturing
    • 3.2.2.2. Ethical issues associated with organoid & spheroid cultures
• 3.3. Organoids & Spheroids Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

• 4.1. Segment Dashboard
• 4.2. Global Organoids & Spheroids Market: Type Movement Analysis
• 4.3. Global Organoids & Spheroids Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Organoids
  • 4.4.1. Organoids market estimates and forecast, 2018 - 2030
  • 4.4.2. Organoids by Type
    • 4.4.2.1. Neural Organoids
    • 4.4.2.1.1. Neural organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.2. Hepatic Organoids
    • 4.4.2.2.1. Hepatic organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.3. Intestinal organoids
    • 4.4.2.3.1. Intestinal organoids market estimates and forecast, 2018 - 2030
    • 4.4.2.4. Other organoids
    • 4.4.2.4.1. Other organoids market estimates and forecast, 2018 - 2030
  • 4.4.3. Organoids by Method
    • 4.4.3.1. General Submerged Method for Organoid Culture
    • 4.4.3.1.1. General Submerged Method for Organoid Culture market estimates and forecast, 2018 - 2030
    • 4.4.3.2. Crypt Organoid Culture Techniques
    • 4.4.3.2.1. Crypt Organoid Culture Techniques market estimates and forecast, 2018 - 2030
    • 4.4.3.3. Air Liquid Interface (ALI) Method for Organoid Culture
    • 4.4.3.3.1. ALI Method for Organoid Culture market estimates and forecast, 2018 - 2030
    • 4.4.3.4. Clonal Organoids from Lgr5+ Cells
    • 4.4.3.4.1. Clonal Organoids from Lgr5+ Cells market estimates and forecast, 2018 - 2030
    • 4.4.3.5. Brain and Retina Organoid Formation Protocol
    • 4.4.3.5.1. Brain and Retina Organoid Formation Protocol market estimates and forecast, 2018 - 2030
    • 4.4.3.6. Others
    • 4.4.3.6.1. Others market estimates and forecast, 2018 - 2030
  • 4.4.4. Organoids by Source
    • 4.4.4.1. Primary Tissues
    • 4.4.4.1.1. Primary tissues market estimates and forecast, 2018 - 2030
    • 4.4.4.2. Stem Cells
    • 4.4.4.2.1. Stem cells market estimates and forecast, 2018 - 2030
• 4.5. Spheroids
  • 4.5.1. Spheroids market estimates and forecast, 2018 - 2030
  • 4.5.2. Spheroids by Type
    • 4.5.2.1. Multicellular tumor spheroids (MCTS)
    • 4.5.2.1.1. MCTS market estimates and forecast, 2018 - 2030
    • 4.5.2.2. Neurospheres
    • 4.5.2.2.1. Neurospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.3. Mammospheres
    • 4.5.2.3.1. Mammospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.4. Hepatospheres
    • 4.5.2.4.1. Hepatospheres market estimates and forecast, 2018 - 2030
    • 4.5.2.5. Embryoid bodies
    • 4.5.2.5.1. Embryoid bodies market estimates and forecast, 2018 - 2030
  • 4.5.3. Spheroids by Method
    • 4.5.3.1. Micropatterned Plates
    • 4.5.3.1.1. Micropatterned Plates market estimates and forecast, 2018 - 2030
    • 4.5.3.2. Low Cell Attachment Plates
    • 4.5.3.2.1. Low Cell Attachment Plates market estimates and forecast, 2018 - 2030
    • 4.5.3.3. Hanging Drop Method
    • 4.5.3.3.1. Hanging Drop Method for spheroid Culture market estimates and forecast, 2018 - 2030
    • 4.5.3.4. Others
    • 4.5.3.4.1. Other methods for spheroid culture market estimates and forecast, 2018 - 2030
  • 4.5.4. Spheroids by Source
    • 4.5.4.1. Cell Line
    • 4.5.4.1.1. Cell line market estimates and forecast, 2018 - 2030
    • 4.5.4.2. Primary Cell
    • 4.5.4.2.1. Primary cell market estimates and forecast, 2018 - 2030
    • 4.5.4.3. iPSCs Derived Cells
    • 4.5.4.3.1. iPSCs Derived Cells market estimates and forecast, 2018 - 2030

Chapter 5. End-Use Business Analysis

• 5.1. Segment Dashboard
• 5.2. Global Organoids & Spheroids Market: End Use Movement Analysis
• 5.3. Global Organoids & Spheroids Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Biotechnology and Pharmaceutical Industries
  • 5.4.1. Biotechnology and Pharmaceutical Industries market estimates and forecast 2018 to 2030 (USD million)
• 5.5. Academic & Research Institutes
  • 5.5.1. Academic & Research Institutes market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Hospitals and Diagnostic Centers
  • 5.6.1. Hospitals and Diagnostic Centers market estimates and forecast 2018 to 2030 (USD million)

Chapter 6. Application Business Analysis

• 6.1. Segment Dashboard
• 6.2. Global Organoids & Spheroids Market: Application Movement Analysis
• 6.3. Global Organoids & Spheroids Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Developmental Biology
  • 6.4.1. Developmental Biology market estimates and forecast 2018 to 2030 (USD million)
• 6.5. Personalized Medicine
  • 6.5.1. Personalized Medicine market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Regenerative Medicine
  • 6.6.1. Regenerative Medicine market estimates and forecast 2018 to 2030 (USD million)
• 6.7. Disease Pathology Studies
  • 6.7.1. Disease Pathology Studies market estimates and forecast 2018 to 2030 (USD Million)
• 6.8. Drug Toxicity & Efficacy Testing
  • 6.8.1. Drug Toxicity & Efficacy Testing market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Regional Business Analysis, by Country, Type, Application, & End-use

• 7.1. Segment Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. North America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. U.S. Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Canada Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.4. Europe
  • 7.4.1. Europe Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. UK Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Germany Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. France Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Italy Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Spain Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Denmark Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Target Disease Prevalence
    • 7.4.8.3. Competitive Scenario
    • 7.4.8.4. Sweden Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Target Disease Prevalence
    • 7.4.9.3. Competitive Scenario
    • 7.4.9.4. Norway Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. China Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.3. Japan
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Japan Market estimates and forecast, 2018 - 2030 (Volume, Thousand)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. India Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Competitive Scenario
    • 7.5.5.4. Australia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Competitive Scenario
    • 7.5.6.4. Thailand Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Competitive Scenario
    • 7.5.7.4. South Korea Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.6. Latin America
  • 7.6.1. Latin America Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Brazil Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.3. Mexico
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Mexico Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.6.4. Argentina
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Argentina Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
• 7.7. MEA
  • 7.7.1. MEA Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Competitive Scenario
    • 7.7.2.4. Saudi Arabia Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.3. South Africa
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Competitive Scenario
    • 7.7.3.4. South Africa Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Target Disease Prevalence
    • 7.7.4.3. Competitive Scenario
    • 7.7.4.4. UAE Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Target Disease Prevalence
    • 7.7.5.3. Competitive Scenario
    • 7.7.5.4. Kuwait Market estimates and forecast, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Lonza
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. 3D Biomatrix
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. 3D Biotek LLC
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. AMS Biotechnology (Europe) Limited
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Cellesce Ltd
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Corning Incorporated
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Greiner Bio-One
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Hubrecht Organoid Technology (HUB)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. InSphero
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Prellis Biologics
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. STEMCELL Technologies Inc.
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives

관련자료